Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin G antibody against SARS-CoV-2 spike protein or nucleocapsid protein (IgG against SARS-CoV-2 S/N protein)
- Target
- IgG against SARS-CoV-2 S/N protein
- Molecular classification
- Immunoglobulin (antibody), Other (biomarker/generic immune effector)
01
Overview
Immunoglobulin G (IgG) antibodies against the SARS-CoV-2 spike protein or nucleocapsid protein develop as part of the adaptive immune response after infection with SARS-CoV-2 or vaccination. Anti-spike IgG can neutralize the virus by blocking its interaction with the host ACE2 receptor, while anti-nucleocapsid IgG reflects prior viral exposure but is not neutralizing. These antibodies are widely used as **serological biomarkers** to assess previous infection or vaccine-induced immunity in patients, but they are **not direct therapeutic targets**. The spike and nucleocapsid proteins themselves are the canonical viral targets for immune responses and for some COVID-19 drugs and vaccines[1][2][3][4][5][6][7][9].
- Other names
- Anti-SARS-CoV-2 spike protein IgGAnti-SARS-CoV-2 nucleocapsid protein IgGSARS-CoV-2 S protein IgGSARS-CoV-2 N protein IgGCOVID-19 serology IgG (spike/nucleocapsid)
02
Mechanism of action
Neutralization of viral particles (anti-spike IgG blocks viral entry into host cells)[3][5][7][9] Opsonization and elimination of virus-infected cells (general role of anti-viral IgG) Diagnostic detection (used in serological assays)
03
Biological functions
Immune responseVirus neutralization (for anti-spike IgG)Diagnostic biomarker (serology)
04
Disease associations
Infection (specifically COVID-19)
05
Safety considerations
Potential for cross-reactivity with other coronaviruses (false positives in serology)Does not indicate current infection or protect all individuals equally (diagnostic limitations)
06
Biomarkers
Presence of IgG against spike protein: marker of prior infection or vaccination[3][5][9]Presence of IgG against nucleocapsid protein: marker of prior infection (not induced by spike-protein-only vaccines)[2][4][6]
Beyond the preview
Go deeper on Immunoglobulin G antibody against SARS-CoV-2 spike protein or nucleocapsid protein (IgG against SARS-CoV-2 S/N protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin G antibody against SARS-CoV-2 spike protein or nucleocapsid protein (IgG against SARS-CoV-2 S/N protein).